Curcumin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Question book-new.svg
 This article relies on references to primary sources or sources affiliated with the subject, rather than references from independent authors and third-party publications. Please add citations from reliable sources. (December 2011)
Curcumin
Skeletal formula
Enol form
Skeletal formula
Keto form
Ball-and-stick model
Ball-and-stick model
IUPAC name

(1E,6E)-1,7-bis (4-hydroxy-
3-methoxyphenyl) -1,6-
heptadiene-3,5-dione
Other names

curcumin
diferuloylmethane
C.I. 75300
Natural Yellow 3
Identifiers
CAS number 458-37-7 YesY
PubChem 969516
ChemSpider 839564 YesY
UNII IT942ZTH98 YesY
ChEBI CHEBI:3962 YesY
ChEMBL CHEMBL116438 N
Jmol-3D images Image 1
Properties
Molecular formula C21H20O6
Molar mass 368.38 g/mol
Appearance Bright yellow-orange powder
Melting point

183 °C (361 °F) (456.15 K)
 N (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Curcumin is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). The other two curcuminoids are desmethoxycurcumin and bis-desmethoxycurcumin. The curcuminoids are natural phenols and are responsible for the yellow color of turmeric. Curcumin can exist in several tautomeric forms, including a 1,3-diketo form and two equivalent enol forms. The enol form is more energetically stable in the solid phase and in solution.[1]

Curcumin can be used for boron quantification in the curcumin method. It reacts with boric acid forming a red colored compound, known as rosocyanine.

Curcumin is brightly yellow colored and may be used as a food coloring. As a food additive, its E number is E100.[2]

Curcumin

Contents

[edit] Chemistry

Curcumin incorporates several functional groups. The aromatic ring systems, which are polyphenols are connected by two α,β-unsaturated carbonyl groups. The diketones form stable enols or are easily deprotonated and form enolates, while the α,β-unsaturated carbonyl is a good Michael acceptor and undergoes nucleophilic addition. The structure was first identified in 1910 by J. Miłobędzka, Stanisław Kostanecki and Wiktor Lampe.[3]

Curcumin is used as a reagent for boron in EPA Method 212.3.[4]

[edit] Biosynthesis

The biosynthetic route of curcumin has proven to be very difficult for researchers to determine. In 1973 Roughly and Whiting proposed two mechanisms for curcumin biosynthesis. The first mechanism involved a chain extension reaction by cinnamic acid and 5 malonyl-CoA molecules that eventually arylized into a curcuminoid. The second mechanism involved two cinnamate units being coupled together by malonyl-CoA. Both mechanisms use cinnamic acid as their starting point, which is derived from the amino acid phenylalanine. This is noteworthy because plant biosyntheses employing cinnamic acid as a starting point are rare compared to the more common use of p-coumaric acid.[5] Only a few identified compounds, such as anigorufone and pinosylvin, use cinnamic acid as their start molecule.[6][7] An experimentally backed route was not presented until 2008. This proposed biosynthetic route follows both the first and second mechanisms suggested by Roughley and Whiting. However, the labeling data supported the first mechanism model in which 5 malonyl-CoA molecules react with cinnamic acid to form curcumin. However, the sequencing in which the functional groups, the alcohol and the methoxy, introduce themselves onto the curcuminoid seems to support more strongly the second proposed mechanism.[5] Therefore, it was concluded the second pathway proposed by Roughly and Whiting was correct.

Biosynthetic pathway of curcumin in Curcuma longa.[5]

[edit] Demonstrated medical uses

A daily dose of 2 grams of Curcuma domestica extract was found to provide pain relief that was equivalent to ibuprofen for the relief of pain associated with osteoarthritis of the knee.[8] An extensive survey of the literature shows a number of other potential uses and that daily doses over a 3 month period of up to 12 grams proved safe.[9] Commercial capsules of curcumin contain piperine, a compound found in pepper which aids absorption of curcumin into the blood stream. However, as curcuma is known to inhibit blood clotting, it should be avoided for a two week period prior to major surgery and not used in conjunction with blood thinners such as warfarin and Plavix. It is also known to aggravate gallstone problems.[10]

[edit] Potential medical uses

Unbalanced scales.svg
 The neutrality of this section is disputed. Please see the discussion on the talk page. Please do not remove this message until the dispute is resolved. (December 2011)

Turmeric has been used historically as a component of Indian Ayurvedic medicine thousand year ago from the period of Charak & Shusruta to treat a wide variety of ailments. Research in the latter half of the 20th century has identified curcumin as responsible for most of the biological activity of turmeric.[11] In vitro and animal studies have suggested a wide range of potential therapeutic or preventive effects associated with curcumin. At present, these effects have not been confirmed in humans. However, as of 2008, numerous clinical trials in humans were underway, studying the effect of curcumin on various diseases, including multiple myeloma, pancreatic cancer, myelodysplastic syndromes, colon cancer, psoriasis, and Alzheimer's disease.[12]

In vitro and animal studies have proven that curcumin has antitumor,[13][14][15] antioxidant, antiarthritic, antiamyloid, anti-ischemic,[16] and anti-inflammatory properties.[17] Anti-inflammatory properties may be due to inhibition of eicosanoid biosynthesis.[18] In addition it may be effective in treating malaria, prevention of cervical cancer, and may interfere with the replication of the human immunodeficiency virus (HIV).[19] In HIV, it appears to act by interfering with P300/CREB-binding protein (CBP). It is also hepatoprotective.[20] A 2008 study at Michigan State University showed low concentrations of curcumin interfere with Herpes simplex virus-1 (HSV-1) replication. The same study showed curcumin inhibited the recruitment of RNA polymerase II to viral DNA, thus inhibiting its transcription. This effect was shown to be independent of effect on histone acetyltransferase activities of p300/CBP.[21] A previous (1999) study performed at University of Cincinnati indicated curcumin is significantly associated with protection from infection by HSV-2 in animal models of intravaginal infections.[22]

Curcumin acts as a free radical scavenger and antioxidant, inhibiting lipid peroxidation and oxidative DNA damage.[23] Curcuminoids induce glutathione S-transferase and are potent inhibitors of cytochrome P450.

The Siegel Life Project funded an initial study on curcumin for Alzheimer's in 1997-1998 through the UCLA Center on Aging. UCLA/VA researchers Drs. Cole and Frautschy presented potent anti-Alzheimer's effects in 1997 and 2000 at the Society for Neuroscience.[24][25] These data were then published in 2001, demonstrating that curcumin was particularly effective in reducing neurodegeneration, oxidative damage, diffuse plaque deposition, aberrant inflammation and impaired inflammatory clearance following beta-amyloid infusion, which was published in 2001.[26] This led to testing in a transgenic animal model where it was shown to dramatically diminish plaque burden and overall inflammation, but also increase plaque associated inflammatory cells suggesting clearance.[27] In 2004 this UCLA/Veterans group demonstrated that the effect was in part to the highly specific binding effects to beta-amyloid, whereby it could break apart amyloid aggregates in vitro, bind to plaques in vivo, and because of its fluorescent properties, it could be determined that plaques of transgenic mice ingesting curcumin fluoresced green, demonstrating brain penetration.[28] A Harvard group showed that 7 days of tail vein injections of curcumin shrunk plaque size and reduced dystrophic neurites.[29] The UCLA group also showed curcumin synerigizing with fish oil working to protect against cognitive deficits in another transgenic model.[30] However humans show much more glucuronidation than rodents, and glucuronidated curcumin does not pass the blood brain barrier (See section on curcumin formulations). Free curcumin but not glucuronidated curcumin readily passes through the barrier. But extensive glucuronidation in humans is the major barrier to translation in neurodegenerative diseases. Human intestinal cells glucuronidate more than rodent intestine (Ireson) [31]

There is also circumstantial evidence curcumin improves mental functions; a survey of 1010 Asian people who ate yellow curry and were between the ages of 60 and 93 showed those who ate the sauce "once every six months" or more had higher MMSE results than those who did not.[32] From a scientific standpoint, though, this does not show whether the curry caused it, or people who had healthy habits also tended to eat the curry, or some completely different relationship.

Numerous studies have demonstrated curcumin, amongst only a few other things, such as high impact exercise, learning, bright light, and antidepressant usage, has a positive effect on neurogenesis in the hippocampus and concentrations of brain-derived neurotrophic factor (BDNF), reductions in both of which are associated with stress, depression, and anxiety.[33][34][35] Curcumin has also been demonstrated to be a selective monoamine oxidase inhibitor (MAOI) of type MAO-A.[citation needed] Fluorescent imaging in a mouse model of Alzheimer's disease showed that curcumin crosses the blood-brain barrier.[36] Several studies have demonstrated that unlike glucuronidated curcumin, free curcumin, which is lipophilic, readily passes the blood brain barrier.[37][38]

In 2009, an Iranian group demonstrated the combination effect of curcumin with 24 antibiotics against Staphylococcus aureus. In that study, in the presence of a subinhibitory concentration of curcumin, the antibacterial activities of cefixime, cefotaxime, vancomycin and tetracycline were increased against test strain. The increase in inhibition zone surface area for these antibiotics were 52.6% (cefixime), 24.9% (cephotaxime), 26.5% (vancomycin ) and 24.4% (tetracycline). Also it showed curcumin has an antagonist effect on the antibacterial effect of nalidixic acid against the test strain.[39]

Although many preclinical studies suggest curcumin may be useful for the prevention and treatment of several diseases, the effectiveness of curcumin has not yet been demonstrated in randomized, placebo-controlled, double-blind clinical trials.[40]

In 2008 scientists at the Salk Institute performed high throughput screening, identifying a curcumin pyrazole derivative, which improved memory, was broadly neuroprotective, and stimulated BDNF both in vitro and in vivo.[41][42] This group showed, in collaboration with UCLA, that it was protective in brain trauma and, in collaboration with Cedars Sinai/UCSD groups, that it was protective in stroke.[43] [44]

[edit] Anticarcinogenic effects

Its potential anticancer effects stem from its ability to induce apoptosis in cancer cells without cytotoxic effects on healthy cells. Curcumin can interfere with the activity of the transcription factor NF-κB, which has been linked to a number of inflammatory diseases such as cancer.[45]

A 2009 study suggested curcumin may inhibit mTOR complex I via a novel mechanism.[46]

Another 2009 study on curcumin effects on cancer states it "modulates growth of tumor cells through regulation of multiple cell signaling pathways including cell proliferation pathway (cyclin D1, c-myc), cell survival pathway (Bcl-2, Bcl-xL, cFLIP, XIAP, c-IAP1), caspase activation pathway (caspase-8, 3, 9), tumor suppressor pathway (p53, p21) death receptor pathway (DR4, DR5), mitochondrial pathways, and protein kinase pathway (JNK, Akt, and AMPK)".[47]

A 2010 study in malignant brain tumors showed curcumin effectively inhibits tumor cell proliferation, as well as migration and invasion, and these effects may be mediated through interference with the STAT3 signaling pathway.[48]

When 0.2% curcumin is added to diet given to rats or mice previously given a carcinogen, it significantly reduces colon carcinogenesis.[49]

Curcumin has recently been shown to have phyto-estrogenic activity that might contribute to activity against breast cancer.[50] In the murine model of breast cancer metastasis, curcumin inhibits the formation of lung metastases [51] probably through the NF-kappa-B dependent regulation of protumorigenic inflammatory cytokines.[52]

Curcumin might be potentially useful in some kidney diseases by preventing renal inflammation.[53]

[edit] Bioavailability

There have been several commercial products developed to provide an alternative route to curcumin. Several trials with unformulated curcumin show extensive glucuronidation and sulfation and typically undetectable levels of free curcumin.[54][55] For example, trials show that ingestion from 2 to 10 grams of unformulated curcumin lead to undetectable or very low serum levels of free curcumin.[56] For neurodegenerative diseases, it is important that curcumin is absorbed predominantly as 'free" as opposed to glucuronidated, since glucuronidated curcumin does not penetrate the blood brain barrier, while free curcumin is readily brain penetrant.[37]

The first formulation to improve bioavailability was curcumin supplements with piperine ("bioperine", manufactured by Sabinsa Corp, New Jersey) and distributed by several companies. Co-supplementation with 20 mg of piperine (extracted from black pepper) significantly increased the absorption of curcumin by 2000% in a study funded by the manufacturer of piperine.[56] However, the increase in absorption in plasma only occurred during the first hour, after which the difference between the piperine curcumin and the regular curcumin was almost the same as far as absorption. It is important to recognize that rapid clearance from plasma after acute administration is not likely to represent levels in tissues such as adipose, breast or brain.[37] Glucuronidation inhibitors should be taken cautiously (if at all) by individuals taking other medications, and whether the doses of piperine used can dramatically increase clinical impact is as yet inconclusive.

The second major commercial innovation of curcumin bioavailability was made in 2006, when UC Regents and the Veterans Administration filed a provisional patent, which led to Longvida Optimized Curcumin. In July 2008, the inventors described a new form of "lipidated curcumin" from Verdure Sciences as "Longvida" that was noted to achieve more than 5 micromolar in the brain in vivo in a mouse study.[37] Pharmacokinetics of Longvida in humans shows superior absorption of free curcumin.[57] Extensive toxicity studies have been performed showing Longvida to have an excellent safety profile.[58] as was found in the NIH cancer toxicity studies with tumeric oleoresin leading it to be placed on the FDA's GRAS (generally recognized as safe) list.[59] New clinical data on this formulation has recently been reported.

Another method to increase the bioavailability of curcumin was later developed as Meriva, patent pending since 2006[60] and involves a simple procedure creating a complex with soy phospholipids. However, there was no plasma concentration of free curcumin found in humans. In animals, free curcumin reaching 33.4 nanomolar while in humans, zero was detected.[61]

Another curcumin proprietary formulation was introduced in 2008 (BCM-95®, Biocurcumax, Arjuna) mixed with turmeric oils, was reviewed in human cross-over bioavailability comparison tests to have 8 times the bioavailability and greater blood retention time than standard 95% curcuminoids extract, and up to 5 times more than curcumin combined with lecithin and piperine.[62] In another study published in a non-medical business journal, this same formula was also shown to remain above 200 ng/g for 12 hours in a human clinical study. Plain curcumin remained above 200 ng/g for less than 2 hours. Two hours after ingestion, BCM-95 levels of free curcumin were 10-fold over that of plain curcumin.[63] However, a subsequent study found no curcumin was absorbed from BCM-95 when it is taken for more than one single dose. In this six-month placebo-controlled, double-blind clinical trial in Alzheimer's disease, individuals in the BCM-95 groups even doses as high as 4 g failed to yield any significant free curcumin in the plasma, nor clinical effect. Interestingly there was a non-significant increase in serum amyloid beta with the high dose, which may relate to some effect on amyloid clearance from the brain. ”.[64]

There are other formulations for curcumin in the pipeline, that have not yet become commercial. In 2007, a polymeric nanoparticle-encapsulated formulation of curcumin made on the lab scale ("nanocurcumin"[65]). Nanocurcumin particles are typically used for needle injection treatments, since they have a size of less than 100 nanometers on average, are unstable in the gut and demonstrate marginal efficacy compared to free curcumin in test tubes of human cancer cell line models.[65] However, actual in vivo absorption (injected or oral) should be tested with this nanoparticle.

In 2010, a food-grade polymer micellar encapsulation system was shown to increase curcumin's water solubility and in vitro anti-cancer activity. It was found that hydrophobically modified starch, usually used to encapsulate flavors, was able to form polymer micelles. Using a simple high-speed homogenization method, it can load curcumin into its hydrophobic core, and thus solubilize curcumin. Cell culture experiments revealed an enhanced anti-cancer activity on HepG2 cell line. However, more in vivo studies are needed to further prove its efficacy in the aspect of bioavailability.[66]

Populations ingesting high amounts of curcumin in foods may have reduced risk for some diseases (Parkinson's), which may be due to an effect of cooking or dissolution in oil. Some benefits of curcumin, such as the benefits for the gut, may not require systemic absorption. Likewise, traditional use in India suggests dissolving curcumin in warm oils prior to ingestion increases bioavailability. Several forms based on this concept are now available, however not all of them are proven to absorb intact into the bloodstream.[61]

[edit] Potential risks and side effects

Extensive in vivo toxicity studies have been performed with turmeric Oleoresin (85% curcumin) which led to it being placed on the FDA's GRAS (generally recognized as safe) list [54]. Kawanishi et al. (2005) remarked that curcumin, like many antioxidants, can be a "double-edged sword" where, in the test tube, anticancer and antioxidant effects may be seen in addition to pro-oxidant effects.[67] Carcinogenic effects are inferred from interference with the p53 tumor suppressor pathway, an important factor in human colon cancer.[68] Carcinogenic and LD50 tests in mice and rats, however, have failed to establish a clear relationship between tumorogenesis and administration of curcumin in turmeric oleoresin at >98% concentrations.[69] Other in vitro and in vivo studies suggest that curcumin may cause carcinogenic effects under specific conditions.[70][71]

Clinical studies in humans with high doses (2–12 grams) of curcumin have shown few side effects, with some subjects reporting mild nausea or diarrhea.[72] More recently, curcumin was found to alter iron metabolism by chelating iron and suppressing the protein hepcidin, potentially causing iron deficiency in susceptible patients.[73] Further studies seem to be necessary to establish the benefit/risk profile of curcumin.[74]

There is no or little evidence to suggest curcumin is either safe or unsafe for pregnant women. However, there is still some concern medicinal use of products containing curcumin could stimulate the uterus, which may lead to a miscarriage, although there is not much evidence to support this claim. According to experiments done on rats and guinea pigs, there is no obvious effect (neither positive, nor negative) on the pregnancy rate or number of live or dead embryos.[75] Curcumin has embryotoxic and teratogenic effects on zebrafishes (Danio rerio) embryos.[76]

[edit] References

Notes
  1. ^ Kolev, Tsonko M.; et al. (2005). "DFT and Experimental Studies of the Structure and Vibrational Spectra of Curcumin". International Journal of Quantum Chemistry (Wiley Periodicals) 102 (6): 1069–79. doi:10.1002/qua.20469. 
  2. ^ Food Standards Australia New Zealand. "Food Additives- Numerical List". http://www.foodstandards.gov.au/newsroom/publications/choosingtherightstuff/foodadditivesnumeric1680.cfm. Retrieved 2 December 2009. 
  3. ^ J. Miłobȩdzka, St. v. Kostanecki, V. Lampe (1910). "Zur Kenntnis des Curcumins". Berichte der deutschen chemischen Gesellschaft 43 (2): 2163–2170. doi:10.1002/cber.191004302168. 
  4. ^ Methods for the Chemical Analysis of Water and Wastes (MCAWW) (EPA/600/4-79/020)
  5. ^ a b c Kita, T., et al. (2008). "The biosynthetic pathway of curcuminoid in turmeric (Curcuma longa) as revealed by 13C-labeled precursors". Bioscience, Biotechnology, and Biochemistry 72 (7): 1789–1798. doi:10.1271/bbb.80075. 
  6. ^ Schmitt, B.; Holscher, D.; Schneider, B. (2000). "Variability of phenylpropanoid precursors in the biosynthesis of phenylphenalenones in Anigozanthos preissii". Phytochemistry 53 (3): 331–337. doi:10.1016/S0031-9422(99)00544-0. PMID 10703053. 
  7. ^ Gehlert, R.; Schoeppner, A.; Kindl, H. (1990). "Stilbene synthase from seedlings of Pinus sylvestris: purification and induction in response to fungal infection". Molecular Plant-Microbe Interactions 3 (6): 444–449. doi:10.1094/MPMI-3-444. 
  8. ^ Kuptniratsaikul, V; Kuptniratsaikul V., et al. (August 15, 2009). "Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis". The Journal of Alternative and Complementary Medicine 15 (8): 891–7. doi:10.1089/acm.2008.0186. PMID 19678780. http://www.ncbi.nlm.nih.gov/pubmed/19678780. Retrieved October 20, 2011. "C. domestica extracts seem to be similarly efficacious and safe as ibuprofen for the treatment of knee OA." 
  9. ^ "Curcumin as "Curecumin": from kitchen to clinic". Biochem Pharmacol. 75 (4): 787–809. February 15, 2008; electronic publication: August 19, 2007,. doi:10.1016/j.bcp.2007.08.016. PMID 17900536. http://www.ncbi.nlm.nih.gov/pubmed/17900536. Retrieved October 20, 2011. "Pilot phase I clinical trials have shown curcumin to be safe even when consumed at a daily dose of 12g for 3 months." 
  10. ^ O'Connor, Anahad (October 19, 2011). "The Doctor’s Remedy: Turmeric for Joint Pain". The New York Times. http://well.blogs.nytimes.com/2011/10/19/the-doctors-remedy-turmeric-for-joint-pain/. Retrieved October 20, 2011. 
  11. ^ Aggarwal BB, et al. (2007). "Curcumin: the Indian solid gold". Adv. Exp. Med. Biol.. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 595: 1–75. doi:10.1007/978-0-387-46401-5_1. ISBN 978-0-387-46400-8. PMID 17569205. 
  12. ^ Hatcher H., et al. (June 2008). "Curcumin: from ancient medicine to current clinical trials". Cell. Mol. Life Sci. 65 (11): 1631–52. doi:10.1007/s00018-008-7452-4. PMID 18324353. 
  13. ^ Ströfer M, Jelkmann W, Depping R.,"Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF." Strahlenther Onkol. 2011 Jul;187(7):393-400
  14. ^ Aggarwal, BB.; Shishodia S. (May 2006). "Molecular targets of dietary agents for prevention and therapy of cancer". Biochemical Pharmacology (Elsevier) 71 (10): 1397–421. doi:10.1016/j.bcp.2006.02.009. PMID 16563357. 
  15. ^ Choi, Hyunsung; et al. (July 2006). "Curcumin Inhibits Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear Translocator: A Mechanism of Tumor Growth Inhibition". Molecular Pharmacology (American Society for Pharmacology and Experimental Therapeutics) 70 (5): 1664–71. doi:10.1124/mol.106.025817. PMID 16880289. 
  16. ^ Shukla PK., et al. title = Anti-ischemic effect of curcumin in rat brain (2008). Neurochemical research 33 (6): 1036–43. doi:10.1007/s11064-007-9547-y. PMID 18204970. 
  17. ^ Stix, Gary (February 2007). "Spice Healer". Scientific American. http://sciam.com/article.cfm?chanID=sa006&articleID=131CED4F-E7F2-99DF-3C84BB412D1D3B51&pageNumber=1&catID=2. 
  18. ^ Srivastava, KC; Bordia A; Verma SK (April 1995). "Curcumin, a major component of the food spice turmeric (Curcuma longa), inhibits aggregation and alters eicosanoid metabolism in human blood platelets". Prostaglandins Leukot Essent Fatty Acids 52 (4): 223–7. doi:10.1016/0952-3278(95)90040-3. PMID 7784468. 
  19. ^ Padma, TV (2005-03-11). "Turmeric can combat malaria, cancer virus and HIV". SciDev.net. http://www.scidev.net/News/index.cfm?fuseaction=readNews&itemid=1987&language=1. 
  20. ^ Marotta, F.; et al. (October 2003). "Hepatoprotective effect of a curcumin/absinthium compound in experimental severe liver injury". Chinese Journal of Digestive Diseases (Blackwell Publishing) 4 (3): 122–7. doi:10.1046/j.1443-9573.2003.00133.x. 
  21. ^ Kutluay SB, et al. (January 2008). "Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity". Virology 373 (2): 239–47. doi:10.1016/j.virol.2007.11.028. PMC 2668156. PMID 18191976. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2668156. 
  22. ^ Bourne KZ, Bourne N, Reising SF, Stanberry LR (1999 July). "Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2". Antiviral research 42 (3): 219–26. doi:10.1016/S0166-3542(99)00020-0. PMID 10443534. 
  23. ^ "Protective effect of curcumin against lead neurotoxicity in rat". Human & experimental toxicology 22 (12): 653–8. 2003. doi:10.1191/0960327103ht411oa. PMID 14992327. 
  24. ^ Sigel, JJ, et al. (1997). "Effects of NSAIDs on Toxin Production and Aβ clearance in a murine microglial cell line". 27th Annual Meeting Society for Neuroscience 23: 635.1. 
  25. ^ Frautschy, SA, et al. (Fall 2000). "Prevention of Aß amyloid peptide infusion induced behavioral deficits neuroinflammation and neurodegeneration by dietary anti-inflammatory antioxidant supplements". 20th Annual Meeting Society for Neuroscience. New Orleans LA 26. 
  26. ^ Frautschy, S.A., et al. (Nov 2001). "Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropatholo". Neurobiol Aging 22 (6): 993–1005. doi:10.1016/S0197-4580(01)00300-1. PMID 11755008. 
  27. ^ Lim, G.P., et al. (2001). "The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse". J Neurosci 21 (21): 8370–7. PMID 11606625. 
  28. ^ Yang, F., et al. (February 2005). "Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo". Journal of Biological Chemistry (American Society for Biochemistry and Molecular Biology) 280 (7): 5892–901. doi:10.1074/jbc.M404751200. PMID 15590663. 
  29. ^ Ran, C., et al. (2007). "Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits". J Neurochem 102 (4): 1095–104. doi:10.1111/j.1471-4159.2007.04613.x. PMID 17472706. 
  30. ^ Ma, Qui-lan, et al. (2009). "Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin". J. Neuroscience 29 (28): 9078–89. doi:10.1523/JNEUROSCI.1071-09.2009. PMID 19605645. 
  31. ^ Ireson, CR, et al. (2002). "Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine". Cancer Epidemiol Biomarkers Prev. 11 (1): 105–11. PMID 11815407. 
  32. ^ Ng TP, et al. (November 2006). "Curry consumption and cognitive function in the elderly". American Journal of Epidemiology (Oxford University Press) 164 (9): 898–906. doi:10.1093/aje/kwj267. PMID 16870699. 
  33. ^ Xu Y, et al. (August 2007). "Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats". Brain Res 1162: 9–18. doi:10.1016/j.brainres.2007.05.071. PMID 17617388. 
  34. ^ Wu A, Ying Z, Gomez-Pinilla F. (February 2006). "Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition". Experimental Neurology 197 (2): 309–17. doi:10.1016/j.expneurol.2005.09.004. PMID 16364299. 
  35. ^ Bala K, Tripathy BC, Sharma D. (April 2006). "Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions". Biogerontology 7 (2): 81–9. doi:10.1007/s10522-006-6495-x. PMID 16802111. 
  36. ^ M. Garcia-Alloza, et al., (2007). "Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model,". J. Neurochem. 102. doi:10.1111/j.1471-4159.2007.04613.x]. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2007.04613.x/abstract. 
  37. ^ a b c d Begum AN, et al. (July 2008). "Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease". J Pharmacol Exp Ther 326 (1): 196–208. doi:10.1124/jpet.108.137455. PMC 2527621. PMID 18417733. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2527621. 
  38. ^ Yang, Fusheng, et al. (2005). "Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo". J. Biol. Chem. 280 (7): 5892–901.. doi:10.1074/jbc.M404751200. PMID 15590663. 
  39. ^ Shahverdi, Ahmadreza et al. (2009). "The combination effect of curcumin with different antibiotics against Staphylococcus aureus". International Journal of Green Pharmacy 3 (2): 141. doi:10.4103/0973-8258.54906. 
  40. ^ Mancuso C, Barone E (2009). "Curcumin in clinical practice: myth or reality?". Trends Pharmacol Sci. 30 (7): 333–4. doi:10.1016/j.tips.2009.04.004. PMID 19523696. 
  41. ^ Maher, Pam, et al. (2010). "A pyrazole derivative of curcumin enhances memory". Neurobiol Aging. 31 (4): 706–9. doi:10.1016/j.neurobiolaging.2008.05.020. PMID 18639368. 
  42. ^ Liu, Y., et al. (2008). "A broadly neuroprotective derivative of curcumin". J Neurochem 105 (4): 1336–45. doi:10.1111/j.1471-4159.2008.05236.x. PMID 18208543. 
  43. ^ Wu, A., et al. (2011). "Brain and spinal cord interaction: a dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma". Neurorehabil Neural Repair 25 (4): 332–42. doi:10.1177/1545968310397706. PMID 21343524. 
  44. ^ Lapchak, Paul; Schubert DR, Maher PA. (2011). "Delayed Treatment with a Novel Neurotrophic Compound Reduces Behavioral Deficits in Rabbit Ischemic Stroke". J Neurochem 116 (1): 122–31. doi:10.1111/j.1471-4159.2010.07090.x. PMC 3004475. PMID 21054387. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3004475. 
  45. ^ Aggarwal, BB; Shishodia, S (2004). "Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning". Annals of the New York Academy of Sciences 1030: 434–41. doi:10.1196/annals.1329.054. PMID 15659827. 
  46. ^ Beevers CS, et al. (February 2009). "Curcumin disrupts the Mammalian target of rapamycin-raptor complex". Cancer Res. 69 (3): 1000–8. doi:10.1158/0008-5472.CAN-08-2367. PMID 19176385. 
  47. ^ Ravindran, J; Prasad, S; Aggarwal, BB (2009). "Curcumin and Cancer Cells: How Many Ways Can Curry Kill Tumor Cells Selectively?". The AAPS journal 11 (3): 495–510. doi:10.1208/s12248-009-9128-x. PMC 2758121. PMID 19590964. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2758121. 
  48. ^ Senft, Christian, et al. (2010). "The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas". BMC Cancer 10: 491. doi:10.1186/1471-2407-10-491. PMC 2949804. PMID 20840775. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2949804. 
  49. ^ Data from sixteen scientific articles reported in the Chemoprevention Database
  50. ^ Bachmeier, B.E., et al. (2010). "Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin". Cell Physiol Biochem 26 (3): 471–82. doi:10.1159/000320570. PMID 20798532. 
  51. ^ Bachmeier, B., et al. (2007). "The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice". Cell Physiol Biochem 19 (1–4): 137–52. doi:10.1159/000099202. PMID 17310108. 
  52. ^ Bachmeier, B.E., et al. (2008). "Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB". Carcinogenesis 29 (4): 779–89. doi:10.1093/carcin/bgm248. PMID 17999991. 
  53. ^ Zhong F, et al. (2011). "Curcumin attenuates lipopolysaccharide-induced renal inflammation.". Biol Pharm Bull (2): 226-32. 
  54. ^ Baum, Larry, et al. (2008). "Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease". J Clin Psychopharmacol. ;28 (1): 110–3. doi:10.1097/jcp.0b013e318160862c. PMID 18204357. 
  55. ^ Anand P., et al. (2007). "Bioavailability of curcumin: problems and promises". Molecular pharmaceutics 4 (6): 807–18. doi:10.1021/mp700113r. PMID 17999464. 
  56. ^ a b Shoba G., et al. (May 1998). "Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers". Planta Med 64 (4): 353–6. doi:10.1055/s-2006-957450. PMID 9619120. 
  57. ^ Gota, V.S, et al. (2010). "Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers". J Agric Food Chem. 58 (4): 2095–9.. doi:10.1021/jf9024807. PMID 20092313. 
  58. ^ Dadhaniya, P., et al. (2011). "Safety assessment of a solid lipid curcumin particle preparation: Acute and subchronic toxicity studies". Food Chem Toxicol. 49 (8):  :1834–42. doi:10.1016/j.fct.2011.05.001. PMID 21571027. 
  59. ^ National Toxicology, Program (1993). "NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies)". Natl Toxicol Program Tech Rep Ser. 427: 1–275.. PMID 12616304. 
  60. ^ European patent EP20060004820
  61. ^ a b Marczylo TH, et al. (2007). "Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine". Cancer Chemother Pharmacol 60 (2): 171–7. doi:10.1007/s00280-006-0355-x. PMID 17051370. 
  62. ^ Antony Bet al. (2008). A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax™) a novel bioenhanced preparation of curcumin.. pp. 445-449. 
  63. ^ Benny B, Antony B. (2006). "Bioavailability of Biocurcumax (BCM-95).". Spice India: 11-15. 
  64. ^ Baum L, et al. (2008). "Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease". J Clin Psychopharmacol 28 (1): 110-3. 
  65. ^ a b Bisht, Savita; et al. (2007). "Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy". Journal of Nanobiotechnology (BioMed Central) 5 (3): 3. doi:10.1186/1477-3155-5-3. PMC 1868037. PMID 17439648. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1868037. 
  66. ^ Yu, Hailong; Huang, Qingrong (2010). "Enhanced in vitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch". Food Chemistry 119 (2): 669. doi:10.1016/j.foodchem.2009.07.018. 
  67. ^ Kawanishi, S; Oikawa, S; Murata, M; (2005). "Evaluation for safety of antioxidant chemopreventive agents". Antioxidants & Redox Signaling 7 (11–12): 1728–39. doi:10.1089/ars.2005.7.1728. PMID 16356133. 
  68. ^ Moos PJ; et al. (2004). "Curcumin impairs tumor suppressor p53 function in colon cancer cells". Carcinogenesis 25 (9): 1611–7. doi:10.1093/carcin/bgh163. PMID 15090465. 
  69. ^ Lois Swirsky Gold. Turmeric (>98% curcurmin). Carcinogenic Potency Database Project. Last updated 3 Apr 2006. Last accessed 4 Jan 2007. [1]
  70. ^ Dance-Barnes ST, et al. (2009). "Lung tumor promotion by curcumin". Carcinogenesis 30 (6): 1016–23. doi:10.1093/carcin/bgp082. PMC 2691137. PMID 19359593. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2691137. 
  71. ^ López-Lázaro M (2008). "Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent". Mol Nutr Food Res. 52 (Suppl 1): S103–S27. doi:10.1002/mnfr.200700238. PMID 18496811. 
  72. ^ Hsu CH, Cheng AL (2007). "Clinical studies with curcumin". Adv. Exp. Med. Biol.. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 595: 471–80. doi:10.1007/978-0-387-46401-5_21. ISBN 978-0-387-46400-8. PMID 17569225. 
  73. ^ Jiao Y, Wilkinson J, Di X, et al. (January 2009). "Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator". Blood 113 (2): 462–9. doi:10.1182/blood-2008-05-155952. PMC 2615657. PMID 18815282. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2615657. 
  74. ^ Burgos-Moron E, et al. (20010). "The dark side of curcumin". Int J Cancer. 126 (7): 1771–5. doi:10.1002/ijc.24967. PMID 19830693. http://onlinelibrary.wiley.com/doi/10.1002/ijc.24967/pdf. .
  75. ^ Vijayalaxmi. (1980). "Genetic effects of turmeric and curcumin in mice and rats". Mutat Res. 79 (2): 125–32. doi:10.1016/0165-1218(80)90080-4. PMID 7432370. 
  76. ^ Wu, Jheng-Yu, et al. (2007). "Curcumin Affects Development of Zebrafish Embryo". Biol. Pharm. Bull: 1336-1339. doi:10.1248/bpb.30.1336. 

[edit] External links

Types of curcuminoids
Curcuminoids
Retrieved from "http://en.wikipedia.org/w/index.php?title=Curcumin&oldid=475833313"
Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages